Trial in Adult Subjects With Spinocerebellar Ataxia
Active, not recruiting
Cognitive Research Corporation
Phase 2/Phase 3
The primary purpose of this study is to compare the efficacy of BHV-4157 (Troriluzole) 140
milligrams (mg) once daily versus placebo after 8 weeks of treatment in subjects with
spinocerebellar ataxia (SCA).
Trial in Adult Subjects With Spinocerebellar Ataxia
Active, not recruiting
Cytel Inc.
Phase 2/Phase 3
The primary purpose of this study is to compare the efficacy of BHV-4157 (Troriluzole) 140
milligrams (mg) once daily versus placebo after 8 weeks of treatment in subjects with
spinocerebellar ataxia (SCA).
Trial in Adult Subjects With Spinocerebellar Ataxia
Active, not recruiting
Biohaven Pharmaceutical Holding Company Ltd.
Phase 2/Phase 3
The primary purpose of this study is to compare the efficacy of BHV-4157 (Troriluzole) 140
milligrams (mg) once daily versus placebo after 8 weeks of treatment in subjects with
spinocerebellar ataxia (SCA).
Trial in Adult Subjects With Spinocerebellar Ataxia
Active, not recruiting
Biohaven Pharmaceuticals, Inc.
Phase 2/Phase 3
The primary purpose of this study is to compare the efficacy of BHV-4157 (Troriluzole) 140
milligrams (mg) once daily versus placebo after 8 weeks of treatment in subjects with
spinocerebellar ataxia (SCA).
Preclinical models suggest that riluzole, the active metabolite of BHV-4157, may protect from
AD-related pathology and cognitive dysfunction. Titrated dose of BHV-4157 to 280 mg, or
placebo, taken orally once daily. Duration of treatment is 48 weeks. There is also a
screening period of up to 42 days; and a 4-week post-treatment observation period.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
